Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
Status:
Not yet recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
HIV infection, as well as exposure to opioids (including heroin), are associated with
systemic immune activation including increased microbial translocation from the gut. The
overall objective of this study is to define the impact of long-term mu-opiate receptor
stimulation or blockage with medication for opiate use disorder (i.e, methadone,
buprenorphine/naloxone, or extended-release naltrexone) on the kinetics and extent of immune
reconstitution on HIV-1 infected people who inject opiate and initiating antiretroviral
therapy.
Phase:
Phase 2
Details
Lead Sponsor:
University of Pennsylvania
Collaborators:
Ho Chi Minh City CDC IMEA Paris National Institute of Drug Abuse The Wistar Institute
Treatments:
Buprenorphine Buprenorphine, Naloxone Drug Combination Methadone Naloxone Naltrexone